This study evaluated superoxide dismutase activity released from human umbilical veins incubated with different doses of heparin and examined at different time points.
Ischemia-reperfusion injury generates oxygen free radicals. In newborns, oxygen free radicals have been implicated in the pathophysiology of many disease processes in newborns, including intraventricular hemorrhage, necrotizing enterocolitis, bronchopulmonary dysplasia, retinopathy of prematurity, renal failure, hypertension, and hypoxic encephalopathy. 1, 2 Sick neonates exposed to high oxygen concentration are susceptible to the formation of oxygen free radicals, including the superoxide radical. The known effects of oxygen-derived free radicals are lipid peroxidation, disulfide cross-linking of proteins in cell membranes, protein strand scission, inhibition of DNA replication, and mutation of genomic DNA, all which lead to cell derangement. 2, 3 Superoxide dismutase (SOD) is an antioxidant enzyme that protects tissues from injury by inactivating oxygen free radicals. It converts superoxide anion to hydrogen peroxide, which is subsequently converted to water by the enzyme catalase. 3 There are three forms of SOD derived from different genes. Manganese SOD is primarily found in the mitochondria, copper-zinc SOD is present in the cytoplasm, and extracellular SOD (EC-SOD) is located on the extracellular matrix of tissues. EC-SOD is the major SOD isoenzyme in extracellular fluids such as plasma, lymph, and synovial fluid. EC-SOD is also present in tissues in higher concentration than in plasma. 4, 5 In the vasculature, EC-SOD is bound to heparan sulfate proteoglycan, a structural component of the extracellular matrix. 5, 6 The glycosoaminoglycan component of heparan sulfate proteoglycan, heparan sulfate, consists of highly sulfated polysaccharides consisting of alternating glucosamine and iduronic or glucuronic acid residues, making it a highly negatively charged molecule. Many other important proteins, such as lipoprotein lipase, hepatic lipase, diamine oxidase, and platelet factor 4 are also bound to heparan sulfate proteoglycan. Due to structural similarities with heparan sulfate, heparin is able to displace EC-SOD and other vascular heparan sulfate proteoglycan-bound proteins and release them into plasma. In adults, a high dose of heparin competitively releases EC-SOD from the vascular matrix into the blood where it is degraded. 7 Since heparin is used clinically in newborns to maintain patency of central arterial and venous catheters, 8, 9 we wanted to determine if this treatment could potentially release SOD from the extracellular matrix of umbilical vessels. The purpose of this study is to determine if heparin releases SOD from umbilical veins at different concentrations and at different time points. We particularly wanted to determine if SOD activity could be released under conditions similar to those used in clinical settings.
MATERIALS AND METHODS
Fresh umbilical cords (25 to 30 cm) were obtained from full-term babies having uncomplicated pre-and perinatal course. These babies Original Article
were delivered at Westchester Medical Center (Valhalla, NY) and Phelps Memorial Hospital (Sleepy Hollow, NY). The cords were placed in a container with Dulbecco's phosphatebuffered saline (DPBS; Life Technologies, Gaithersburg, MD) containing amphotericin B (0.25 g/ml; Fungizone; Apothecon), penicillin (100 U/ml), and streptomycin (100 g/ml).
High-Dose Heparin Study
A 5-Fr umbilical catheter was inserted in the umbilical vein, and the vein was washed with DPBS until clear of blood. The cord was clamped into equal halves using a cord clamp. One half of the cord was filled with DPBS containing 175 U/ml heparin (porcine; Sigma Chemical Co., St. Louis, MO). The other half was filled with an equal volume of DPBS without heparin as control. After clamping the ends, the cords were placed in a container of DPBS and incubated at 37°C.
One ml of the infusate was removed from each end of the umbilical cord at 10 minutes and at 24 hours with a tuberculin syringe, placed into a tube containing EDTA and a mixture of anti-proteases 10 and kept at Ϫ70°C until SOD activity was measured.
Low-Dose Heparin Study
All the steps for the above experiment were repeated, substituting incubation with 1 U/ml and collecting specimens at 10 and 60 minutes.
SOD Assay
The cytochrome c method 11 was used to measure SOD enzymatic activity. Units were determined based on a commercial preparation of SOD from bovine erythrocytes (Sigma). Results are expressed as units per milliliter Ϯ SEM. Significance was determined ( p Ͻ 0.05) using the paired Student's t test.
RESULTS
The results presented in Figures 1 and 2 show a time-dependent release of SOD activity in the presence and absence of heparin. First, we determined whether release of SOD activity could be achieved with a high dose of heparin. Figure 1 shows that 175 U/ml heparin caused a significant increase in the release of SOD from umbilical veins at 10 minutes ( p ϭ 0.02) and at 24 hours ( p ϭ 0.03).
We then determined whether a dose of heparin used for maintaining patency in catheters would release SOD activity. Umbilical veins incubated with low-dose heparin (1 U/ml) showed a significant increase in SOD release at 60 minutes ( p ϭ 0.04) when compared with the control; although the results at 10 minutes were not statistically significant ( p ϭ 0.07), they showed an increase in SOD release, as shown in Figure 2 .
DISCUSSION
Advances in neonatal resuscitation and postnatal care have resulted in improved survival rates for premature babies. 12, 13 This progress has been mostly due to surfactant and improved techniques of ventilation of premature lungs. Although these measures are lifesaving, there is considerable evidence that hyperoxia leads to multiple complications such as retinopathy of prematurity, intraventricular hemorrhage, and chronic lung disease. The common factor in the pathophysiology of these diseases appears to be endothelial cell fragility, leading to capillary damage and hemorrhage. 1 Oxygen free radicals are generated during ischemia-reperfusion injury. According to Granger et al., 14 during ischemia (hypoxia), reduced oxygen leads to decreased production of adenosine triphosphate, causing an accumulation of adenosine diphosphate and aden- osine monophosphate. Adenosine monophosphate is subsequently catabolized to adenosine, inosine, and then hypoxanthine. Along with these changes in energy status, xanthine dehydrogenase is converted by sulfhydryl oxidation or limited proteolysis to xanthine oxidase. 15 When oxygen is reintroduced (reperfusion), these elevated levels of xanthine oxidase and hypoxanthine result in the production of excess superoxide anions and their conversion products, hydrogen peroxide and hydroxyl radicals. The rate of formation of oxygen radicals and related reactive oxygen metabolites is far in excess of antioxidant defense mechanisms of endothelial cells.
Oxygen-derived free radicals cause tissue damage by lipid peroxidation, disulfide cross-linking of proteins in cell membranes, protein strand scission, inhibition of DNA replication, and mutation of genomic DNA. 2, 3, 16 In chronic lung disease, damage primarily involves high oxygen concentration during therapy, whereas, in retinopathy of prematurity and intraventricular hemorrhage, damage results from excess radical production on reperfusion following hyperoxia. In addition, oxygen free radicals have been implicated in pathogenesis of necrotizing enterocolitis, 17 renal failure, 18 hypertension, 19 and hypoxic encephalopathy. 20 Natural antioxidant scavengers like SOD and glutathione have been known to play a role in protecting against oxygen free radicals. Miller et al. 21 showed that SOD prevented damage in a rabbit model of necrotizing enterocolitis. Furthermore, recombinant human SOD has been used in therapeutic trials, 22 which have shown a reduced amount of free radical formation in respiratory distress syndrome.
EC-SOD is the most abundant form of SOD in human umbilical cord tissues, a fact that suggests an important role for EC-SOD in the anti-oxidant system of fetal tissues and newborn infants. EC-SOD is a tetrameric, slightly hydrophobic glycoprotein that contains four copper atoms and four zinc atoms. 23, 24 It differs from other SOD isoenzymes in amino acid composition and antigenic properties. EC-SOD is separated into three fractions depending on affinity for heparin: A, without affinity; B, with weak affinity; and C, with strong affinity. 10 EC-SOD fractions B and C bind to heparan sulfate proteoglycan, which exists in the glycocalyx of cell surfaces and connective tissue matrices. 10 Heparin administration has been shown to release predominantly EC-SOD fraction C in adult human studies. 7 For other proteins with heparin affinity, such as lipoprotein lipase, hepatic lipase, diamine oxidase and platelet factor 4, it has been found that injection of heparin also leads to increases in the plasma content of these proteins. [25] [26] [27] The release of these factors into plasma is apparently a result of displacement from heparin analogues on vascular endothelial-cell surfaces.
Our results showed a significant increase in SOD activity when umbilical cord veins were incubated with a high dose of heparin, analogous to previous reports. 7 The important part of our study was to determine if SOD activity is released at doses of heparin routinely used in neonatal practice. When umbilical veins were incubated with heparin at a dose of 1 U/ml, there was a significant increase in SOD activity at 1 hour of incubation while at 10 minutes there was an increase that did not reach significance, when compared with the control without heparin.
To explain the SOD activity release in the absence of heparin, Ohta et al. 28 have suggested in vivo partial degradation of EC-SOD by proteolytic activity. This action results in separating the HS-binding portion of the molecule from the solubilized catalytic portion. The high-dose heparin study used 10-minute and 24-hour time points, with significant increase in the release of SOD activity seen at both times. Because there would be time over 24 hours for endogenous proteolytic digestion of SOD, we used 1 hour as our second time point in the subsequent low-dose heparin study. Even at 60 minutes, significant SOD activity was released. At 24 hours, the high doses of heparin may have released an even greater level of SOD activity than the apparent amount that was measured.
These results lead us to postulate that heparin, given through umbilical catheters, may dislodge SOD activity, which may alter a newborn's susceptibility to oxygen free radicals.
